Metal Chelation Therapy for Neurodegenerative Diseases

Migration, Crosslink

📖

Metal Chelation Therapy for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-metal-chelation-therap

📖 Wiki Page

therapeutic1123 wordssynced 2026-04-02

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metal Chelation Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Iron (Fe³⁺)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Hydroxamate siderophore</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Clinical Use</td>
<td>FDA approved for iron overload</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Iron (Fe³⁺)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Bidentate hydroxyphenylisoxazole</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Clinical Use</td>
<td>FDA approved for iron overload</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Copper, Zinc</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>8-hydroxyquinoline</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Discontinued</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Copper, Zinc</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>8-hydroxyquinoline (synth

...

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metal Chelation Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Iron (Fe³⁺)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Hydroxamate siderophore</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Clinical Use</td>
<td>FDA approved for iron overload</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Iron (Fe³⁺)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Bidentate hydroxyphenylisoxazole</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Clinical Use</td>
<td>FDA approved for iron overload</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Copper, Zinc</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>8-hydroxyquinoline</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Discontinued</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Copper, Zinc</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>8-hydroxyquinoline (synthetic)</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>High</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">VAR10403</td>
<td>Iron</td>
</tr>
<tr>
<td class="label">M30</td>
<td>Iron, copper</td>
</tr>
<tr>
<td class="label">DP-b99</td>
<td>Iron, copper</td>
</tr>
<tr>
<td class="label">Trientine</td>
<td>Copper</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Deferoxamine + CoQ10</td>
<td>Iron removal + mitochondrial support</td>
</tr>
<tr>
<td class="label">PBT2 + Memantine</td>
<td>Metal homeostasis + [NMDA](/entities/nmda-receptor) modulation</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Use</td>
</tr>
<tr>
<td class="label">Serum ferritin</td>
<td>Iron status</td>
</tr>
<tr>
<td class="label">CSF ferritin</td>
<td>Brain iron</td>
</tr>
<tr>
<td class="label">MRI (R2*)</td>
<td>Brain iron quantification</td>
</tr>
<tr>
<td class="label">DMT1 expression</td>
<td>Iron transport</td>
</tr>
</table>

Metal Chelation Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Metal chelation therapy aims to restore metal homeostasis in the brain by removing excess transition metals that contribute to oxidative stress, protein aggregation, and neuronal death. Iron and copper accumulation is a hallmark of many neurodegenerative diseases, making metal homeostasis a compelling therapeutic target [@ward2014]. [@zecca2004]

Pathogenic Role of Metal Dysregulation

Iron in Neurodegeneration

Iron accumulation occurs with aging and is accelerated in: [@crapper1991]

Alzheimer's Disease: Iron co-localizes with amyloid plaques and neurofibrillary tangles
Parkinson's Disease: Iron elevation in substantia nigra correlates with dopaminergic neuron loss
ALS: Iron accumulation in motor [cortex](/brain-regions/cortex) and spinal cord
Huntington's Disease: Elevated iron in striatum and cortex [@zecca2004]

Copper Dysregulation

Reduced copper in [neurons](/entities/neurons) despite elevated extracellular copper
Copper deficiency impairs cytochrome c oxidase (Complex IV)
Copper can catalyze toxic [reactive oxygen species](/entities/reactive-oxygen-species) formation

Zinc Homeostasis

Zinc dysregulation affects synaptic function
Zinc can promote [Aβ](/proteins/amyloid-beta) aggregation
Altered zinc transporters in AD and PD

Chelating Agents

Deferoxamine (Desferal)

Evidence in Neurodegeneration:

Reduced MRI iron signals in PD patients
Slowed cognitive decline in AD (limited trials)
Preclinical studies show neuroprotection [@crapper1991]

Deferasirox (Jadenu, Exjade)

Clinical Trials:

Phase 2 trial in PD (completed)
Phase 2 trial in AD (recruiting)
Better tolerability than deferoxamine [@devos2014]

Clioquinol (PBT1)

Clinical Trials:

Phase 2 in AD showed reduced cognitive decline
Discontinued due to formulation issues
Led to second-generation compounds [@ritchie2003]

PBT2

Clinical Trials:

Phase 2A in AD: Reduced [Aβ42](/proteins/amyloid-beta) in CSF
Phase 2 in PD: Ongoing
Improved blood-brain barrier penetration [@lannfelt2008]

Other Chelators in Development

Disease-Specific Applications

Alzheimer's Disease

Rationale:

Iron and copper promote Aβ aggregation
Metal-induced oxidative stress
Metal-dependent amyloid processing enzymes

Clinical Evidence:

Deferoxamine: Mixed results, limited by route
Clioquinol: Positive Phase 2
PBT2: Reduced CSF Aβ42, improved cognition [@ayton2015]

Parkinson's Disease

Rationale:

Iron elevation in substantia nigra
Neuromelanin binds iron
Ferritin elevation in CSF

Clinical Evidence:

Deferasirox: Phase 2 completed (NCT01539837)
Phase 2 showed reduced iron in substantia nigra
Ongoing studies in early PD [@martinbastida2020]

Amyotrophic Lateral Sclerosis

Rationale:

Iron accumulation in motor neurons
Elevated ferritin in CSF
Iron-dependent oxidative damage

Clinical Evidence:

Deferoxamine: Small trial showed possible benefit
Iron chelation being explored in combination therapy

Wilson's Disease

Standard of care: Trientine, penicillamine
Neurological symptoms respond to chelation
Early treatment prevents progression

Combination Approaches

Chelation + Antioxidants

Chelation + Iron Supplements

Careful balance needed - some iron necessary for normal function.

Biomarkers for Monitoring

Adverse Effects and Contraindications

Common Side Effects

Gastrointestinal distress (oral agents)
Injection site reactions (subcutaneous)
Anemia (iron deficiency with overtreatment)
Renal dysfunction

Contraindications

Active infection
Severe anemia
Renal impairment (dose adjustment needed)
Pregnancy (most agents)

Future Directions

Novel Chelators

[Blood-brain barrier](/entities/blood-brain-barrier) penetrating compounds
Metal-specific agents (iron vs copper vs zinc)
Multifunctional agents (chelation + antioxidant + anti-inflammatory)

Combination Strategies

Chelation with antioxidants
Chelation with neuroprotective agents
Gene therapy for metal transport proteins

Precision Medicine

Genetic testing for metal homeostasis genes
Biomarker-guided treatment selection
Individualized chelation protocols

External Links

[ClinicalTrials.gov - Iron Chelation Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=chelation)
[National Institute of Neurological Disorders](https://www.ninds.nih.gov/)

Background

The study of Metal Chelation Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Ward RJ, Zucca FA, Bellei P, et al, Brain iron metabolism: from molecular mechanisms to clinical significance (2014)](https://doi.org/10.1089/ars.2013.2329)

Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, Iron, brain ageing and neurodegenerative disorders (2004)

Crapper McLachlan DR, Dalton AJ, Kruck TP, et al, Intramuscular desferrioxamine in patients with Alzheimer's disease (1991)

Devos D, Moreau C, Devedjian JC, et al, Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARKII study (2014)

Ritchie CW, Bush AI, Mackinnon A, et al, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial (2003)

Lannfelt L, Blennow K, Zetterberg H, et al, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial (2008)

Ayton S, Lei P, Bush AI, Biometals and their therapeutic implications in Alzheimer's disease (2015)

Martin-Bastida A, Lao-Kaim NP, Loane C, et al, Relationship between nigral iron and disease progression in Parkinson's disease: An MRI study (2020)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-metal-chelation-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-metal-chelation-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0345beb080b0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-metal-chelation-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

181

Outgoing

233

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Metal Chelation Therapy for Neurodegenerative Diseases

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

Overview

Pathogenic Role of Metal Dysregulation

Iron in Neurodegeneration

Copper Dysregulation

Zinc Homeostasis

Chelating Agents

Deferoxamine (Desferal)

Deferasirox (Jadenu, Exjade)

Clioquinol (PBT1)

PBT2

Other Chelators in Development

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Wilson's Disease

Combination Approaches

Chelation + Antioxidants

Chelation + Iron Supplements

Biomarkers for Monitoring

Adverse Effects and Contraindications

Common Side Effects

Contraindications

Future Directions

Novel Chelators

Combination Strategies

Precision Medicine

See Also

External Links

Background

References

💬 Discussion

📗 Cite This Artifact

Metal Chelation Therapy for Neurodegenerative Diseases

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

Metal Chelation Therapy for Neurodegenerative Diseases

Introduction

Overview

Pathogenic Role of Metal Dysregulation

Iron in Neurodegeneration

Copper Dysregulation

Zinc Homeostasis

Chelating Agents

Deferoxamine (Desferal)

Deferasirox (Jadenu, Exjade)

Clioquinol (PBT1)

PBT2

Other Chelators in Development

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Wilson's Disease

Combination Approaches

Chelation + Antioxidants

Chelation + Iron Supplements

Biomarkers for Monitoring

Adverse Effects and Contraindications

Common Side Effects

Contraindications

Future Directions

Novel Chelators

Combination Strategies

Precision Medicine

See Also

External Links

Background

References

Related Hypotheses

💬 Discussion